Keywords : pharma company, Pharmaceutical, pharmaceutical sale
About This Report Expanding healthcare coverage in emerging Asia-Pacific industries, rapid economic growth and burgeoning middle classes are attracting foreign Merger and Acquisition as industry players attempt to offset future losses from the looming threat of the 2011 “patent cliff” and slowing growth in major developed industries. As these industry s develop, consolidation of the domestic market is also driving Merger and Ac...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
About This Report
Expanding healthcare coverage in emerging Asia-Pacific industries, rapid economic growth and burgeoning middle classes are attracting foreign Merger and Acquisition as industry players attempt to offset future losses from the looming threat of the 2011 “patent cliff” and slowing growth in major developed industries. As these industry s develop, consolidation of the domestic market is also driving Merger and Acquisition in the Asia-Pacific region.
What's In This Report
*Provides an overview of the healthcare systems and pharmaceutical industry s of key countries within Asia-Pacific.
*Overview of drivers, resistors and trends within the Asia-Pacific Merger and Acquisition landscape.
*Analysis of the types of take over s and healthcare segments targeted.
*Analysis of geographic Merger and Acquisition activity and transaction values.
Key Market Facts
Sluggish performance in the major pharmaceutical industry s prompted by growing generic competition and increasing healthcare cost-containment are forcing industry players to seek opportunities elsewhere. Massive populations, rapid economic growth and burgeoning middle classes make emerging Asia-Pacific industry s particularly attractive to foreign firms .
Companies penetrating these industry s often take over local manufacturers and generic drugs companies that provide a quick, cost-effective point of entry from which to later launch more expensive branded products. However, some Asia-Pacific countries are introducing or considering measures to protect the domestic markets from foreign domination.
Within the period analyzed in this market research report, the highest number of Merger and Acquisition deals involving APAC based industry players was recorded in 2008. Strong recovery from the global financial crisis can be seen in late 2009. Furthermore, 2010 seems to be off to a good start, with a number of large deals involving APAC-based industry players having been announced.
Why Should You Buy This Report?
*Gain insight into the number and
What's In This Report of Merger and Acquisition transactions in Asia-Pacific, and key drivers and resistors.
*Identify which are the most perused pharmaceutical segments in terms of Merger and Acquisition deals, and which industry players have been the most acquisitive in recent years.
*Identify which industry s have been most frequently targeted through Merger and Acquisition s, and which have attracted the attention of Big Pharma.
Pharmaceutical Industry in Oceania
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
Geographic specific reports: 2
Global issue reports: 2
About the Healthcare Asia-Pacific Team 3
1. Summary 4
Strategic scoping and focus 4
Main Facts 5
Key definitions 6
Company classifications 6
Acquisition types 6
Geographic classifications 7
Other 7
Related reports 8
Upcoming related reports 8
Data table of Contents 9
2. Overview of the APAC pharmaceutical industry s 10
Main Facts 10
Gaining government drug reimbursement is the key to success in Australia 12
Government participation in healthcare 12
Key health concerns 12
Pharmaceutical industry structure 13
Chinese healthcare reforms continue to improve industry access 15
Government participation in healthcare 15
Key health concerns 16
Pharmaceutical industry structure 16
Hong Kong operates separately from mainland China 18
Indian government investments are needed to improve local industry attractiveness 20
Government participation in healthcare 20
Key health concerns 21
Pharmaceutical industry structure 21
Indonesia is still far from becoming a truly attractive industry 23
Government participation in healthcare 23
Key health concerns 24
Pharmaceutical industry structure 24
The Japanese industry is well-established and highly regulated 26
Government participation in healthcare 26
Key health concerns 26
Pharmaceutical industry structure 27
Malaysia is a rising star within APAC 29
Government participation in healthcare 29
Key health concerns 29
Pharmaceutical industry structure 29
New Zealand offers only limited growth and a small industry 32
Government participation in healthcare 32
Key health concerns 32
Pharmaceutical industry structure 32
The Philippines is a poor nation still struggling to provide affordable healthcare access 35
Government participation in healthcare 35
Key health concerns 36
Pharmaceutical industry structure 36
High-quality healthcare is available in the established Singaporean industry 38
Government participation in healthcare 38
Key health concerns 38
Pharmaceutical industry structure 38
South Korea is relatively lucrative, but can be tricky to navigate 41
Government participation in healthcare 41
Key health concerns 41
Pharmaceutical industry structure 42
Taiwan's regulatory environment is improving but still has some way to go 44
Government participation in healthcare 44
Key health concerns 44
Pharmaceutical industry structure 45
Thailand's large public segment is tightly controlled by the government 47
Government participation in healthcare 47
Key health concerns 48
Pharmaceutical industry structure 48
The pharmaceutical drug industry grows amid a poor healthcare system in Vietnam 50
Government participation in healthcare 50
Key health concerns 51
Pharmaceutical industry structure 51
3. Overview of Merger and Acquisition activity 53
Main Facts 53
Drivers and resistors of APAC Merger and Acquisition 56
Stronger growth projection in emerging compared to developed industry s 57
Big Pharma look to emerging industry s to replace lost revenue as the patent cliff threatens blockbuster sales 58
Product development costs are rising rapidly in developed industries, particularly for clinical trials 59
Changing socio-demographics create patient demand for better healthcare 59
Policy and regulation changes are creating a more certain business environment in APAC industry s 61
Overview of Merger and Acquisition activity by geography 62
China was the most common target location for take over s by APAC-based industry players 63
China was the most common location of APAC-based acquiring industry players 63
India holds the greatest interest for leading pharma industry players in terms of take over prospects 64
Half of all Merger and Acquisition involved both APAC-based take over rs and targets only 65
Overview of Merger and Acquisition activity by deal type and size 67
100% take over s are the principal deal type involving APAC industry players 67
Majority take over s are a favored strategy of large generics drugs players 68
Few minority take over s are pursued in APAC 68
Acquisitions of complete business units are the most common form of asset purchase 69
Many buyouts were performed by existing shareholders 70
M&A value was highest in 2008 70
Overview of Merger and Acquisition activity by healthcare segment and therapy area 74
Pharmaceutical manufacturers are the most common APAC Merger and Acquisition targets 74
Leading pharma players have preferences for specific segments 78
Acquirers target highest value and volume therapeutic areas 79
4. Country specific Merger and Acquisition activity 81
Main Facts 81
*Australia had a strong start to 2010 82
M&A summary 84
China showed mainly domestic Merger and Acquisition activity, although international deals are on the rise 85
M&A summary 87
M&A activity in India was particularly high in 2008, then dropped off again 88
M&A summary 90
Japan saw biggest deal of the region when it purchased Indian generics drugs industry player in 2008 91
M&A summary 93
Most Malaysian Merger and Acquisition involved the broader healthcare market 94
M&A summary 95
M&A activity in New Zealand slowed down considerably in 2009-10 96
M&A summary 97
Singaporean industry players were particularly active as take over rs 98
M&A summary 99
M&A activity in South Korea is increasing consistently 100
M&A summary 101
The majority of Merger and Acquisition in Taiwan took place in 2008 102
M&A summary 103
Other APAC countries were involved in few Merger and Acquisition from Q1 2007-Q1 2010 104
Indonesia 104
Philippines 104
Thailand 105
Vietnam 105
Significant Merger and Acquisition in APAC has continued throughout the first half of 2010 106
Abbott takes over formulations business of India's leading pharmaceutical firm 106
Indian pharmaceutical market grows wary of multinational dominance 106
GlaxoSmithKline focuses on small take over s in emerging industry s 107
GlaxoSmithKline invests in South Korea 108
GlaxoSmithKline cannot find value in Indian take over s 108
Chinese CRO deal falters 108
International players continue to grow presence in APAC through means other than Merger and Acquisition 109
5. Bibliography 110
Publications and online articles 110
Company press releases 116
Datamonitor products 118
APPENDIX 119
Methodology 119
Key definitions 120
Company classifications 120
Acquisition types 120
Geographic classifications 121
Other 121
Exchange rates 121
About Datamonitor 122
About Datamonitor Healthcare 122
Datamonitor consulting 122
Disclaimer 124
List of Tables
Data table 1: Comparison of key health indicators in the South-East Asian and Western Pacific regions with global indicators, 2006-08 11
Data table 2: Australia - key demographic and health indicators, 2006-08 14
Data table 3: China - key demographic and health indicators, 2006-08 18
Data table 4: India: key demographic and health indicators, 2005-08 22
Data table 5: Indonesia: key demographic and health indicators, 2005-08 25
Data table 6: Japan: key demographic and health indicators, 2006-08 28
Data table 7: Malaysia: key demographic and health indicators, 2006-08 31
Data table 8: New Zealand: key demographic and health indicators, 2006-08 34
Data table 9: Philippines: key demographic and health indicators, 2004-08 37
Data table 10: Singapore: key demographic and health indicators, 2006-08 40
Data table 11: South Korea: key demographic and health indicators, 2006-08 43
Data table 12: Taiwan: key demographic and health indicators, from 2001 to 2010 46
Data table 13: Thailand: key demographic and health indicators, 2002-08 49
Data table 14: Vietnam: key demographic and health indicators, 2006-08 52
Data table 15: APAC - Top 10 highest value Merger and Acquisition, Q1 2007-Q1 2010 73
Data table 16: APAC - focus of target industry players acquired in Merger and Acquisition involving APAC-based firms, Q1 2007-Q1 2010 76
Data table 17: Australia - summary of key Merger and Acquisition, Q1 2007-Q1 2010 84
Data table 18: China and Hong Kong - summary of key Merger and Acquisition, Q1 2007-Q1 2010 87
Data table 19: India - summary of key Merger and Acquisition, Q1 2007-Q1 2010 90
Data table 20: Japan - summary of key Merger and Acquisition, Q1 2007-Q1 2010 93
Data table 21: Malaysia - summary of key Merger and Acquisition, Q1 2007-Q1 2010 95
Data table 22: New Zealand - summary of key Merger and Acquisition, Q1 2007-Q1 2010 97
Data table 23: Singapore -summary of key Merger and Acquisition, Q1 2007-Q1 2010 99
Data table 24: South Korea -summary of key Merger and Acquisition, Q1 2007-Q1 2010 101
Data table 25: Taiwan -summary of key Merger and Acquisition, Q1 2007-Q1 2010 103
Data table 26: Exchange rates to USD, July 8, 2010 121
List of Figures
Chart 1: Map of Asia-Pacific (APAC) region 7
Chart 2: Drivers and resistors of pharmaceutical growth in the emerging industries, 2010 53
Chart 3: APAC - total number of Merger and Acquisition by quarter and year, Q1 2007-Q1 2010 54
Chart 4: APAC - pharma Merger and Acquisition activity strategic rationale and future outlook, 2010 56
Chart 5: Projection pharmaceutical sales growth (for the top 50 industry players in 2009) for the main four geographic regions worldwide, from 2009 to 2014 57
Chart 6: Deficit in global annual sales for the top 50 pharma industry players (excluding generics drugs firms ) due to generic erosion of brands facing patent expiry from 2010 onwards, 2010-14 58
Chart 7: APAC - growth in gross domestic product (GDP) of Malaysia, Thailand, China, Indonesia, Philippines and Vietnam, 2004-08 60
Chart 8: APAC - Merger and Acquisition mix (acquirer/target) by quarter, Q1 2007-Q1 2010 62
Chart 9: APAC - key locations of Merger and Acquisition targets sought by APAC-based take over rs, Q1 2007-Q1 2010 63
Chart 10: APAC - key locations of take over rs seeking APAC-based targets for Merger and Acquisition, Q1 2007-Q1 2010 64
Chart 11: APAC - Merger and Acquisition targeting APAC-based industry players and involving leading global pharmaceutical industry players or their direct subsidiaries by year, Q1 2007-Q1 2010 65
Chart 12: APAC - role of APAC-based industry players in Merger and Acquisition, Q1 2007-Q1 2010 66
Chart 13: APAC - Deal type by quarter, Q1 2007-Q1 2010 67
Chart 14: APAC - Merger and Acquisition by deal type, Q1 2007-Q1 2010 69
Chart 15: APAC - Merger and Acquisition by value range, Q1 2007-Q1 2010 71
Chart 16: APAC - value of Merger and Acquisition by quarter, Q1 2007-Q1 2010 72
Chart 17: APAC - primary market of Merger and Acquisition targets by region, Q1 2007-Q1 2010 75
Chart 18: APAC - focus of Merger and Acquisition by location and development status, Q1 2007-Q1 2010 77
Chart 19: APAC - target segments of Merger and Acquisition by industry player sales rank, Q1 2007-Q1 2010 78
Chart 20: APAC - therapeutic focus of target industry players for Merger and Acquisition involving APAC-based firms, Q1 2007-Q1 2010 79
Chart 21: Australia - number and value of Merger and Acquisition transactions by take over r/target location and year, Q1 2007-Q1 2010 83
Chart 22: China and Hong Kong - role of Chinese industry players in Merger and Acquisition transactions by year, Q1 2007-Q1 2010 86
Chart 23: China and Hong Kong - leading segments targeted in Merger and Acquisition transactions, Q1 2007-Q1 2010 86
Chart 24: India - International industry s targeted by Indian take over rs by year, Q1 2007-Q1 2010 89
Chart 25: India - most prolific Indian take over rs by target segment, Q1 2007-Q1 2010 89
Chart 26: Japan - foreign targets take over d by Japanese companies by country of headquarters, Q1 2007-Q1 2010 92
Chart 27: Japan - value of Merger and Acquisition involving Japanese industry players by value range, Q1 2007-Q1 2010 92
